Neothetics Announces Issuance by USPTO of Additional Patent Directed to LIPO-202 Lead Clinical Asset

Neothetics, Inc.

, a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the issuance of U.S. Patent No. 9,132,084 by the United States Patent and Trademark Office (USPTO). This marks issuance of the company's third United States patent in its portfolio that is directed to Neothetics' lead asset, LIPO-202, the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects. This particular patent is directed to formulations and methods for reducing adipose tissue using LIPO-202. George Mahaffey, Neothetics' president and chief executive officer, stated: "We are pleased to have received issuance of this most recent patent from the USPTO, which further strengthens our robust intellectual property portfolio protecting our lead body contouring product candidate, LIPO-202, which is currently in pivotal Phase 3 trials."